113 related articles for article (PubMed ID: 27997009)
41. [Clinical significance and mechanism of upregulation of PI3Kp110α in non-small cell lung carcinoma].
Xiong Y; Qu LL; Li D; Wang Y; Li T
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):737-743. PubMed ID: 29061016
[No Abstract] [Full Text] [Related]
42. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
43. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
44. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
[TBL] [Abstract][Full Text] [Related]
45. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
46. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
47. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
[TBL] [Abstract][Full Text] [Related]
48. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway.
Cheng HW; Chen YF; Wong JM; Weng CW; Chen HY; Yu SL; Chen HW; Yuan A; Chen JJ
J Exp Clin Cancer Res; 2017 Feb; 36(1):27. PubMed ID: 28173828
[TBL] [Abstract][Full Text] [Related]
49. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
50. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
51. Understanding and targeting resistance mechanisms in NSCLC.
Rotow J; Bivona TG
Nat Rev Cancer; 2017 Oct; 17(11):637-658. PubMed ID: 29068003
[TBL] [Abstract][Full Text] [Related]
52. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
53. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
54. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
55. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.
Baldi L; Mengoli MC; Bisagni A; Banzi MC; Boni C; Rossi G
Lung Cancer; 2014 Nov; 86(2):291-5. PubMed ID: 25312989
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
57. Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma.
Ge X; Liu Z; Weng S; Xu H; Zhang Y; Liu L; Dang Q; Guo C; Beatson R; Deng J; Han X
Comput Struct Biotechnol J; 2022; 20():3449-3460. PubMed ID: 35832634
[TBL] [Abstract][Full Text] [Related]
58. Oncogenomics.
Gomase VS; Tagore S; Kale KV; Bhiwgade DA
Curr Drug Metab; 2008 Mar; 9(3):199-206. PubMed ID: 18336222
[TBL] [Abstract][Full Text] [Related]
59. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Rajurkar S; Mambetsariev I; Pharaon R; Leach B; Tan T; Kulkarni P; Salgia R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549358
[TBL] [Abstract][Full Text] [Related]
60. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
Neel DS; Bivona TG
NPJ Precis Oncol; 2017; 1():. PubMed ID: 29152593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
